InMed Pharmaceuticals Inc. stocks have been trading up by 40.25 percent following highly positive biotechnology pipeline advancement news.
Click Here for a Millionaire's POV on Trading INM
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Amended all-stock merger pact with Mentari Therapeutics clarifies deal steps, pre-closing financing impact on the share exchange ratio, and intended tax treatment.
- New Form S-4 registration statement and preliminary proxy/prospectus filed with the SEC push the INM–Mentari merger process into the formal regulatory phase.
- Boards of both InMed Pharmaceuticals and Mentari have approved the deal, which targets a Q4 2026 close, pending shareholder votes, S-4 effectiveness, and customary conditions.
Live Update At 10:03:35 EDT: On Wednesday, July 22, 2026 InMed Pharmaceuticals Inc. stock [NASDAQ: INM] is trending up by 40.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
INM has been trading like a classic low-priced biotech with a catalyst. Over the last few weeks, INM’s daily chart shows a slow grind from the $1.50 area to a close at $2.16, with clear signs of expanding range. That steady base around $1.50–$1.60 gave traders a reference level before the latest merger news pushed volatility higher.
On the intraday tape, INM’s 5‑minute chart tells the real story. The stock ripped from sub‑$2 levels in the premarket, briefly spiking above $5.50 before fading and then stabilizing in the low $2s. For active traders, that’s a classic news-driven blowoff move followed by consolidation.
More Breaking News
- Nebius Group NBIS Jumps On $1B AI Compute Deal
- BMNR Stock Climbs As Massive Ethereum Bet Draws Traders
- SMR Stock Holds Key Level As Wall Street Stays Cautious
- INLF Stock Draws Traders After Explosive Multi-Day Run
Fundamentally, InMed Pharmaceuticals is still a money-losing micro-cap. Revenue is roughly $4.9M over the trailing period, but margins are deep in the red and returns on assets and equity are sharply negative. On the flip side, INM shows a current ratio above 3.0 and low debt, which matters for a small biotech burning cash. The balance sheet isn’t pretty, but it is not overleveraged, giving INM some runway while the Mentari deal plays out.
Why Traders Are Watching This Merger
Traders are laser-focused on INM after the company amended its all-stock merger agreement with privately held Mentari Therapeutics. The headline is not about a new product or sudden earnings surprise. It’s about deal mechanics — and those details can move a thin biotech like InMed Pharmaceuticals more than any single quarter of revenue.
The amended agreement tightens the roadmap: it clarifies how the acquisition will sequence, how any pre-closing financing will feed into the exchange ratio, and how the transaction is intended to be treated for tax purposes. For traders, that means less guesswork on the structure but more need to model dilution. Every extra dollar INM raises before closing could shift how many shares Mentari holders receive and how much existing INM holders are effectively diluted.
Filing the Form S‑4 and preliminary proxy/prospectus with the SEC is another key step. It signals that InMed Pharmaceuticals is moving from headline talk to formal documentation. Once the S‑4 is reviewed, traders will get more granular numbers, risk factors, and pro forma ownership details. That’s the material traders in this space wait for.
Board approval on both sides adds credibility that the Mentari merger is not a trial balloon. Still, the targeted Q4 2026 closing date reminds traders this is a long game. Between now and then, INM’s share price will likely swing around funding news, regulatory progress, and biotech sentiment. Active traders will use this merger framework as the backdrop for short-term setups, not as a “set and forget” story.
Conclusion
INM is now a classic event-driven biotech trade. The amended Mentari merger agreement, combined with the new S‑4 filing, gives traders a clearer structure but not a finished picture. InMed Pharmaceuticals still faces heavy losses, negative returns, and ongoing cash burn, even as it maintains a decent liquidity cushion and low leverage. That mix keeps INM squarely in speculative territory.
For short-term traders, the price action around the merger headlines — the wild premarket spike, the intraday fade, and the new base near $2 — offers a roadmap. INM has shown it can move fast on news, which is exactly what momentum traders look for. The real edge now comes from reading each new filing and financing through the lens of exchange ratios and dilution. As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.” Applying that trading mindset to INM means logging how the stock reacts to each filing, headline, and financing so patterns around this merger-driven volatility become clearer over time.
Longer term, the targeted Q4 2026 close means the INM–Mentari story will unfold over years, not weeks. There will be plenty of catalysts: shareholder votes, S‑4 effectiveness, additional capital raises, and any clinical or strategic updates from the combined pipeline. In the words of Tim Sykes, “The market rewards preparation, not prediction — know the catalysts, study the filings, and react to the price action instead of marrying a story.” For traders tracking INM, that mindset is essential as this merger-driven narrative evolves.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.